OKYO Pharma Ltd (OKYO) director buys 25,000 shares, holdings reach 10.85M
Rhea-AI Filing Summary
OKYO Pharma Ltd director and ten percent owner Gabriele M. Cerrone, through Panetta Partners Limited, purchased 25,000 shares of common stock in an open market transaction on July 20, 2026 at $1.40 per share, increasing his indirect holdings to 10,851,416 shares. This amendment corrects the transaction code for that purchase; no other transactions are changed.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 25,000 shares
Net Buy
1 txn
Insider
CERRONE GABRIELE M
Role
Director, 10% Owner
Bought
25,000 shs ($35K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | COMMON STOCK | 25,000 | $1.40 | $35K |
Holdings After Transaction:
COMMON STOCK — 10,851,416 shares (Indirect, Via Panetta Partners Limited)
Key Figures
Shares purchased: 25,000 shares
Purchase price: $1.40 per share
Total indirect holdings after transaction: 10,851,416 shares
+1 more
4 metrics
Shares purchased
25,000 shares
Common stock bought in open market on July 20, 2026
Purchase price
$1.40 per share
Price for OKYO Pharma common stock in the reported transaction
Total indirect holdings after transaction
10,851,416 shares
Common shares held indirectly via Panetta Partners Limited after the purchase
Net insider share change
25,000 shares
Net buy reported in transaction summary for this Form 4/A
Key Terms
open market purchase, ten percent owner, indirect
3 terms
open market purchase financial
"correct the transaction code associated with this open market purchase"
An open market purchase is when a company buys its own shares on public stock exchanges the same way any investor would, rather than through a private deal. Investors care because these purchases reduce the number of shares available, can boost earnings per share and share price, signal that management thinks the stock is undervalued, and use company cash that might otherwise go to reinvestment or dividends — like a business quietly buying back its own tickets at the box office.
ten percent owner financial
"reporting person is a director and is_ten_percent_owner"
indirect financial
"ownership_type is indirect, nature_of_ownership Via Panetta Partners Limited"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did OKYO (OKYO) report in this amended filing?
The filing reports that Gabriele M. Cerrone, a director and ten percent owner of OKYO Pharma, bought 25,000 common shares in an open market purchase on July 20, 2026, held indirectly via Panetta Partners Limited.
What is Gabriele M. Cerrone’s OKYO (OKYO) stake after this transaction?
After the July 20, 2026 trade, Gabriele M. Cerrone’s indirect holdings in OKYO Pharma totaled 10,851,416 common shares, all reported as held indirectly via Panetta Partners Limited following the 25,000-share open market purchase.
Was the OKYO (OKYO) insider purchase made under a Rule 10b5-1 trading plan?
No. The filing’s Rule 10b5-1 checkbox is not marked, indicating the 25,000-share open market purchase by Gabriele M. Cerrone, via Panetta Partners Limited, was not reported as executed under a Rule 10b5-1 trading plan.
Why did OKYO Pharma file an amended Form 4 for this insider transaction?
The amendment was filed solely to correct the transaction code associated with the reported open market purchase. OKYO Pharma states that no other reported transactions are affected, and the underlying 25,000-share buy and holdings remain the same.